Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Payables (2020 - 2026)

PROCEPT BioRobotics has reported Payables over the past 7 years, most recently at $18.9 million for Q1 2026.

  • Quarterly Payables rose 27.14% to $18.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $18.9 million through Mar 2026, up 27.14% year-over-year, with the annual reading at $17.3 million for FY2025, 72.3% up from the prior year.
  • Payables was $18.9 million for Q1 2026 at PROCEPT BioRobotics, up from $17.3 million in the prior quarter.
  • Over five years, Payables peaked at $18.9 million in Q1 2026 and troughed at $2.6 million in Q1 2022.
  • The 5-year median for Payables is $10.3 million (2023), against an average of $11.1 million.
  • Year-over-year, Payables soared 362.84% in 2022 and then dropped 26.31% in 2025.
  • A 5-year view of Payables shows it stood at $9.4 million in 2022, then surged by 43.74% to $13.5 million in 2023, then dropped by 25.68% to $10.0 million in 2024, then surged by 72.3% to $17.3 million in 2025, then rose by 9.06% to $18.9 million in 2026.
  • Per Business Quant, the three most recent readings for PRCT's Payables are $18.9 million (Q1 2026), $17.3 million (Q4 2025), and $11.1 million (Q3 2025).